Mindray And WuXi PharmaTech’s Growth Strategy In 2Q: China Earnings Roundup (Part 1)
This article was originally published in PharmAsia News
Executive Summary
PharmAsia News takes a closer look at how Chinese healthcare companies have fared against the backdrop of a global economic slowdown, starting with two of the country’s leading companies in their respective industries.
You may also be interested in...
China's Leading CROs Go On Shopping Spree To Become One-Stop Vendors
China's leading contract research organizations, Wuxi PharmaTech and ShangPharma, in a race to win over Big Pharma with integrated service platforms, announced separate deals Oct. 24 to expand into new strategic areas
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.